The One Big Beautiful Bill Act (OBBA), signed into law on July 4, 2025, reshaped the US fiscal landscape.
One of its most touted provisions is a tax cut on tips and overtime, putting more money directly into workers' pockets. But while many investors have been looking for that use to show up in consumer goods, one of the biggest beneficiaries has been consumer health care spending.
The law also expanded Health Savings Account (HSA) eligibility and increased FSA limits for dependent care for the first time since 1986. Therefore, employers develop benefits packages. That has been an uphill battle for commercial managed care organizations (MCOs) and pharmacy benefit managers (PBMs).
Another area to consider is the Medicaid cut law. This is expected to be just under $1 trillion over ten years and will pressure insurance companies with heavy exposure to the government system. But for companies that specialize in employer-sponsored and commercial insurance, the outlook is different.
Commercial power is a big difference. OBBA's HSA extensions went live on January 1, 2026: ACA copper and catastrophic marketplace plans are HSA compatible, telehealth is covered before deductibles are met, and FSA dependent care limits are increased to $7,500.
These changes do two things for commercially oriented MCOs and PBMs. First, they expand the number of people covered by an HSA and increase participation in benefit accounts, especially among workers with variable income or significant overtime. Second, by making pre-deductible telehealth coverage permanent, they can move more care through the employer's plan channels, which raises the use of insurers' care management systems and, at the bottom, fill pharmacies through the PBM network.
Therefore, companies that are best positioned to capture that change in commercial healthcare demand tend to have diversified profitability across insurance, pharmacy benefits, and care delivery, as well as the ability to absorb policy noise while taking on growing commercial membership.
UnitedHealth: One Ecosystem, Multiple Entry Points
UnitedHealth Group Today
UnitedHealth Group
- 52 week interval
- $234.60
▼
$387.21
- Dividend Yield
- 2.33%
- The P/E ratio
- 28.66
- Target Value
- $378.88
Company UnitedHealth Group Inc. NYSE: UNH is the largest managed care organization in the United States, accounting for approximately 10% of national health care spending.
Its Optum segment—made up of OptumRx (PBM), OptumHealth, and OptumInsight—offers one of the most integrated commercial health care environments on the market.
That integration is key to understanding how UnitedHealth benefits from OBBA. As employers expand HSA-compliant plan offerings, OptumRx is positioned to capture rising prescription volume and specialty pharmacy growth. The company's acquisition of Alegeus Technologies further strengthens its strength in the management of the profit account.
UNH has had a turbulent year amid DOJ scrutiny and leadership changes. But the basic setup remains the same. In the company's Q1 2026 earnings report, the company reported revenue growth of 2.2% YOY.
UNH is up more than 20% in 30 days. That brought it very close to its consensus price of $378.88. However, since the earnings report was released on April 21, some analysts have issued higher price targets. JPMorgan Chase, for example, reiterated its overweight rating and raised its target to $420 from $389.
Humana: The Rate Tailwind That Changes Calculus
Humana Today
- 52 week interval
- $163.11
▼
$315.35
- Dividend Yield
- 1.29%
- The P/E ratio
- 29.37
- Target Value
- $247.61
Company Humana Inc. NYSE: HUM it's best known as a Medicare Advantage (MA) insurer, but its CenterWell division, which includes pharmacy sales, home health, and primary care, gives it growing commercial exposure.
OBBA's 2.48% MA payout rate for 2027, worth more than $13 billion, directly supports Humana's core business. This was much higher than the 0.09% originally proposed, and markets responded strongly: Humana shares jumped nearly 12% on the news.
In its Q1 2026 earnings report, Humana beat the highs and lows, posting earnings per share (EPS) of $10.31 against the consensus of $9.97. Revenue came in at $39.65 billion, up 23.5% year-over-year (YOY). Its medical loss ratio of 89.4% beat the average of 89.8%.
The company maintained its 2026 EPS guidance of at least $9. HUM stock is above the consensus price target of $247.61, but several analysts have raised their targets since the earnings report was released on April 29. Star ratings (Medicare plan quality scores) remain a headwind for funds watching, but Humana's cost discipline is improving.
CVS: 5 Bits of Earnings and Counting
CVS Health Today
- 52 week interval
- $58.35
▼
$90.89
- Dividend Yield
- 2.94%
- The P/E ratio
- 39.87
- Target Value
- $95.92
CVS Health NYSE: CVS operates three related businesses: Aetna (insurance), Caremark (PBM), and its retail pharmacy network.
OBBA's HSA expansion is particularly important to Caremark, which manages pharmacy benefits for nearly 88 million plan members.
The company's Q1 earnings report on May 6 showed growth. CVS posted EPS of $2.57, beating estimates of $2.21.
The company also raised its full-year 2026 guidance to $7.30-$7.50 a share on revenue of at least $405 billion.
Caremark's revenue rose 11% YOY to $48.2 billion in Q1 2026, driven by increased enrollment in HSA-compatible plans. Aetna's medical profit margin fell sharply to 84.6%, from 87.3% last year, a sign that medical cost discipline is taking hold.
CVS is up more than 13% in the 30 days, putting it within 8% of its consensus price of $95.92.
Before you consider UnitedHealth Group, you'll want to hear this.
MarketBeat tracks Wall Street's top and most effective research analysts and the stocks they recommend to their clients every day. MarketBeat identified five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and UnitedHealth Group wasn't on the list.
Although UnitedHealth Group currently has an Average Buy rating among analysts, top analysts believe these five stocks are the best.
View Five Stocks Here
MarketBeat recently released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
